Does Rallies show 13F holders for GDRX?

Yes. Rallies tracks hedge fund and 13F ownership data for GDRX, including fund names, share counts, latest tracked quarter, and position changes when available.

Is GDRX research on Rallies investment advice?

No. Rallies provides research, data, and educational context for GDRX. It does not provide personalized investment advice.

GDRX (GoodRx Holdings, Inc. Class A Common Stock) Stock Analysis - Hedge Fund Holdings

GoodRx Holdings, Inc. Class A Common Stock (GDRX) is a publicly traded Healthcare sector company. As of May 21, 2026, GDRX trades at $2.49 with a market cap of $846.69M and a P/E ratio of 41.75. GDRX moved -0.20% today. Year to date, GDRX is -10.95%; over the trailing twelve months it is -36.52%. Its 52-week range spans $1.77 to $7.21. Analyst consensus is neutral with an average price target of $3.09. Rallies surfaces GDRX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns GDRX stock?

Hedge funds tracked by Rallies that own GDRX include Eisler Capital and Mangrove Partners. The latest tracked quarter is Jun 30, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for GoodRx Holdings, Inc. Class A Common Stock.

GDRX Key Metrics

Key financial metrics for GDRX
Metric	Value
Price	$2.49
Market Cap	$846.69M
P/E Ratio	41.75
EPS	$0.06
Dividend Yield	0.00%
52-Week High	$7.21
52-Week Low	$1.77
Volume	62.87K
Avg Volume	0
Revenue (TTM)	$787.89M
Net Income	$20.56M
Gross Margin	0.00%

Top Hedge Funds Holding GDRX

Eisler Capital holds 107.11K shares of GDRX, changed +4.84% as of Jun 30, 2024.
Mangrove Partners holds 106.09K shares of GDRX, changed +0.00% as of Dec 31, 2025.

Latest GDRX News

GoodRx Q4 Sales Beat Estimates by 0.8% at $194.8M, 2026 EBITDA Guidance Cut to $230M — Feb 25, 2026
GoodRx Launches Employer Direct to Target Employer Benefits Market — Feb 24, 2026
GoodRx Q4 Revenue Flat at $196 M, 300K Customer Decline Raises Concerns — Feb 24, 2026
GoodRx Rolls Out Weight Loss, Erectile Dysfunction and Hair Loss Digital Care Services — Feb 6, 2026
BofA Cuts GoodRx Target to $2.60 as Wegovy® Pill Priced at $149 — Jan 5, 2026

Recent GDRX Insider Trades

Spectrum Equity VII, L.P. sold 15.20K (~$60.82K) on Oct 15, 2025.
Spectrum Equity VII, L.P. sold 8.57K (~$34.28K) on Oct 15, 2025.
Spectrum Equity VII, L.P. sold 10.24K (~$41.48K) on Sep 5, 2025.

GDRX Analyst Consensus

13 analysts cover GDRX: 0 strong buy, 4 buy, 7 hold, 2 sell, 0 strong sell. Consensus rating is neutral. Average price target: $3.09.

Common questions about GDRX

Who owns GDRX stock?: Hedge funds tracked by Rallies that own GDRX include Eisler Capital and Mangrove Partners. The latest tracked quarter is Jun 30, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for GoodRx Holdings, Inc. Class A Common Stock.
Does Rallies show 13F holders for GDRX?: Yes. Rallies tracks hedge fund and 13F ownership data for GDRX, including fund names, share counts, latest tracked quarter, and position changes when available.
Is GDRX research on Rallies investment advice?: No. Rallies provides research, data, and educational context for GDRX. It does not provide personalized investment advice.